Predictive Oncology Files Definitive Proxy Statement

TL;DR

PRED proxy filing out. Shareholders vote soon on board & pay.

AI Summary

Predictive Oncology Inc. filed a Definitive Proxy Statement (DEF 14A) on August 18, 2025, for the fiscal year ending December 31, 2025. The filing pertains to the company's proxy materials, which are typically distributed to shareholders before annual meetings to solicit votes on matters such as director elections and executive compensation. The company's principal executive offices are located in Pittsburgh, PA.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda for the upcoming shareholder meeting and provides details on corporate governance, director nominations, and executive compensation, enabling informed voting decisions.

Risk Assessment

Risk Level: low — A DEF 14A filing is a routine disclosure and does not inherently indicate new risks for the company.

Key Players & Entities

• Predictive Oncology Inc. (company) — Registrant
• 0001171843-25-005471 (filing_id) — Accession Number
• 20250818 (date) — Filing Date
• 20250919 (date) — Period of Report
• Pittsburgh, PA (location) — Business Address
• Skyline Medical Inc. (company) — Former Company Name

FAQ

Key Financial Figures

• $10,000,000 — 2. To approve the issuance of up to $10,000,000 of the Company’s common stock pur
• $15,000 — . We have agreed to pay Sodali a fee of $15,000, plus out-of-pocket expenses, for these
• $2,500,000 — ot regained compliance with the minimum $2,500,000 stockholders’ equity requirement
• $1.00 — e for our Common Stock had closed below $1.00 per share for 30 consecutive business d

Filing Documents

• def14a_081825.htm (DEF 14A) — 133KB
• 0001171843-25-005471.txt ( ) — 135KB

From the Filing

DEF 14A 1 def14a_081825.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 Predictive Oncology Inc. (Name of registrant as specified in its charter) (Name of person(s) filing proxy statement, if other than the registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 PREDICTIVE ONCOLOGY INC. 91 43 rd Street, Suite 110 Pittsburgh, Pennsylvania 15201 Telephone: (412) 432-1500 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS To Be Held on September 19, 2025 Dear Stockholder: You are cordially invited to attend the Special Meeting of Stockholders (the “Special Meeting”) of Predictive Oncology Inc. (the “Company”) on September 19, 2025, at 12:00 PM (Eastern Time) at the offices of DLA Piper LLP (US) at 1001 Liberty Avenue, Suite 500, Pittsburgh, Pennsylvania, 15222 for the following purposes: 1. To approve an amendment of the Company’s certificate of incorporation, as amended (the “Charter”) to effect a reverse stock split of the outstanding shares of its common stock at a ratio of one-for-fifteen (1:15) (the “Reverse Split Proposal”); 2. To approve the issuance of up to $10,000,000 of the Company’s common stock pursuant to a Standby Equity Purchase Agreement dated July 1, 2025, for purposes of complying with Nasdaq listing rule 5635 (the “Nasdaq Proposal”); and 3. To approve the adjournment of the Special Meeting in the event that the number of shares of common stock present or represented by proxy at the meeting and voting “FOR” the adoption of the foregoing proposals are insufficient to approve such proposals (the “Adjournment Proposal”). These items of business are more fully described in the proxy statement accompanying this Notice. After careful consideration, the Company’s Board of Directors recommends a vote “FOR” the Reverse Split Proposal, “FOR” the Nasdaq Proposal, and “FOR” the Adjournment Proposal. The record date for the Special Meeting is August 18, 2025. Only stockholders of record at the close of business on that date are entitled to vote at the meeting or any adjournment thereof, or by proxy. Your vote is very important. Whether or not you plan to attend the meeting, please sign and submit your proxy as soon as possible so that your shares can be voted at the Special Meeting in accordance with your instructions. If you attend the meeting, you may revoke your proxy in accordance with the procedures set forth in the proxy By Order of the Board of Directors, /s/ Raymond Vennare Raymond Vennare Chief Executive Officer Pittsburgh, Pennsylvania August 18, 2025 The accompanying proxy statement is dated August 18, 2025, and, together with the enclosed form of proxy card, is first being mailed to our stockholders on or about such date. TABLE OF CONTENTS Page Questions and Answers 1 Proposal 1: Reverse Stock Split Proposal 5 Proposal 2: Nasdaq Proposal 10 Proposal 3: Adjournment Proposal 12 General Matters 13 Where You Can Find More Information 13 Stockholder Proposals and Nominations for the 2025 Annual Meeting 13 Other Matters 14 Form of Certificate of Amendment to Certificate of Incorporation, as amended A-1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This proxy statement may contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our current views with respect to, among other things, plans and objectives of management. Examples of forward-looking statements include, among others, statements we make regarding the implementation of the Reverse Stock Split and the potential effects of the Reverse Stock Split, as well as sales of shares of our common stock pursuant to the SEPA (as defined herein), and the effects on our compliance with Nasdaq listing requirements, our market capitalization, and the trading price, marketability and liquidity of our common stock. You can identify these forward-looking statements by the use of forward-looking words such as “will,” “may,” “plan,” “estimate,” “project,” “believe,” “anticipate

View Full Filing

View this DEF 14A filing on SEC EDGAR